Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesObstetrics/GynecologyAetna Female Sexual Dysfunction Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0574

    Female Sexual Dysfunction (FSD)

    Customize your policy alerts

    Sign up for Aetna Policy 0574 alerts

    Get alerted when Policy 0574 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing diagnostic and therapeutic interventions for female sexual dysfunction, including coverage stance on specific devices, procedures, and drugs; applies to Aetna plans and providers evaluating or requesting coverage for treatments for FSD.

    Policy Summary
    PayerAetna
    PolicyFemale Sexual Dysfunction (FSD)
    Policy CodePolicy 0574
    Change TypeNo material change
    Effective DateNov 9, 2001
    Last ReviewJul 28, 2023
    Next Review DateJun 13, 2024
    Key ActionDocument indication and prior therapies when requesting coverage for bremelanotide or ospemifene and check plan-specific prior authorization requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~20document chunks reviewed
    1related policy referenced
    Multipleexperimental interventions
    4 systemsICD/CPT/HCPCS codes referenced
    insufficientevidence insufficiency noted

    Coverage stance and evidence summaries

    Covered vs Experimental/Investigational and DME stance

    Summary coverage stance and key medical necessity points from this part of the policy:

    General medical necessity/coverage stance: Ospemifene (Osphena) is recognized for treatment of moderate-to-severe dyspareunia due to vulvar and vaginal atrophy in postmenopausal women when used per prescribing information; many other listed interventions are considered experimental/investigational due to insufficient evidence.

    See specific contraindications and boxed warnings in the background section.

    Interventions considered experimental/investigational: Bibliotherapy; Biothesiometry; Botulinum toxin; Female erectile devices (e.g., Eros device); Gene therapy; Growth factor therapy; Hyaluronic acid; Laser therapy (e.g., micro-ablative CO2 laser); Oxytocin; Percutaneous tibial nerve stimulation; PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); Progesterone; Radiofrequency thermal therapy (e.g., ThermiVa, Viveve); Regenerative medicine; Sacral neuromodulation; Stem cell-based therapies; Testosterone implants/injections; Topical lidocaine; Transcranial direct current; Vaginal electrical stimulation.

    Listed as experimental/investigational due to insufficient evidence.

    Policy Summary
    PayerAetna
    PolicyFemale Sexual Dysfunction (FSD)
    Policy CodePolicy 0574
    Change TypeNo material change
    Effective DateNov 9, 2001
    Last ReviewJul 28, 2023
    Next Review DateJun 13, 2024
    Key ActionDocument indication and prior therapies when requesting coverage for bremelanotide or ospemifene and check plan-specific prior authorization requirements.
    SourceLink
    On This Page
    Coverage stance and evidence summariesCodes referenced by the policyPrior authorization, documentation, and prescribing guidanceClinical background and contextKey terms and definitionsPolicy dates and document history
    DME exclusion: Vibrators are not covered as DME because they are not primarily medical devices and may be used in the absence of illness or injury; check benefit plan descriptions for exclusions of drugs or supplies for sexual dysfunction.

    Coverage may vary by plan.

    Evidence summaries and implied coverage stance

    Summaries of evidence and regulatory positions for selected FSD interventions in these document chunks:

    Energy-based devices (lasers, radiofrequency): FDA has raised concerns about use of lasers and energy-based devices for 'vaginal rejuvenation' and off-label treatment of sexual function or menopause-related gynecologic conditions; adverse events reported include vaginal burns, scarring, and chronic pain. Evidence for safety and effectiveness for these indications is inadequate.

    FDA communications and review of adverse events cited.

    Micro-ablative CO2 and erbium lasers: Observational studies and small trials report symptom improvement (e.g., dyspareunia, dryness, FSFI) but studies are small, heterogeneous, and at risk of bias; reviewers concluded benefits are suggested but not established by high-quality RCTs.

    Multiple systematic reviews and small studies reported; benefit not consistently proven.

    Bremelanotide (Vyleesi): Phase-III trials demonstrated statistically significant increases in sexual desire and reductions in distress in pre-menopausal women with HSDD; common adverse events include nausea, flushing, and headache; prescribing info limits dosing and indicates discontinuation after 8 weeks without benefit.

    Indicated for acquired generalized HSDD in pre-menopausal women only.

    Topical agents (DHEA, hyaluronic acid, vaginal estrogens): Topical DHEA showed evidence of improved sexual function in cancer survivors; systematic review suggests hyaluronic acid has efficacy comparable to vaginal estrogens for vaginal atrophy outcomes, but heterogeneity limits meta-analysis and larger trials are needed.

    Potential alternative for women who cannot use hormonal therapy.

    Neuromodulation (PTNS, SNM): Systematic reviews/meta-analyses show small trials with some positive effects of PTNS and sacral neuromodulation on sexual function in women with pelvic floor disorders, but larger studies with sexual function as a primary outcome are recommended.

    Evidence promising but limited.

    Bibliotherapy and psychotherapeutic approaches: Bibliotherapy and psychotherapeutic interventions show indications of benefit for sexual function, particularly in women, but overall evidence certainty is very low due to study limitations.

    Further high-quality trials needed.

    Evidence Summary

    Evidence summary relevant to coverage consideration:

    HA and vaginal suppositories evidence: Systematic reviews identify potential benefit of hyaluronic acid and vaginal suppositories (with vitamins A/E, alpha-tocopherol acetate, dienestrol) for reducing dyspareunia, vaginal mucosal inflammation, dryness, bleeding, fibrosis and cellular atypia in women treated with pelvic radiotherapy or brachytherapy; however, studies used heterogeneous outcome measures and were small (total N=376 in reviewed population).

    Authors conclude data are insufficient and large randomized placebo-controlled trials are needed before standard therapy adoption.

    Aetna does not cover vibrators as durable medical equipment because they do not meet the plan’s contractual definition of DME; vibrators are not primarily medical devices and may be of use in the absence of illness or injury. Check applicable benefit plan descriptions for any additional exclusions of drugs or supplies for sexual dysfunction.

    The FDA has raised concerns about the use of lasers and other energy-based devices marketed for “vaginal rejuvenation” to treat gynecologic conditions, menopause-related symptoms, urinary incontinence, or sexual function, noting these uses lack adequate evidence and have been associated with serious harms (for example, vaginal burns, scarring, chronic pain).

    Use of laser and other energy-based devices for vaginal “rejuvenation” or to treat sexual function or menopause-related gynecologic conditions is discouraged outside FDA‑cleared indications because safety and effectiveness for these indications have not been established.

    Systematic reviews and small trials of topical agents such as hyaluronic acid and vaginal suppositories report potential benefit for symptoms (eg, dyspareunia, dryness, mucosal inflammation) in select populations, but study heterogeneity and small sample sizes limit definitive conclusions; authors state larger randomized, placebo‑controlled trials are needed before these interventions can be considered standard therapy.

    Several interventions included in this policy (for example, biothesiometry, botulinum toxin, hyaluronic acid, radiofrequency procedures, laser therapy, sacral neuromodulation, stem-cell and regenerative approaches, and various topical or device-based therapies) are classified as experimental and investigational due to insufficient evidence and are therefore not established as covered treatments.

    Published studies of radiofrequency procedures (eg, ThermiVa, Viveve) include methodological limitations (small or selective samples, post-hoc analyses, lack of blinding) and investigators note a lack of evidence regarding effectiveness for vaginal rejuvenation, FSD, and other gynecologic disorders.

    Procedures using energy-based devices marketed for “vaginal rejuvenation” to treat sexual dysfunction or related gynecologic conditions lack adequate evidence of safety and effectiveness; the FDA has warned clinicians and patients about deceptive marketing and documented adverse events for these off‑label uses.

    Although some small studies report symptom improvement with interventions such as hyaluronic acid suppositories, the policy notes there is insufficient evidence to support routine adoption of these therapies and calls for larger randomized, placebo‑controlled trials.

    Codes referenced by the policy

    Codes mentioned in policy coding sectionmixed
    0552TLow-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional.
    0672TEndovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence.
    17110Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions [micro-ablative carbon dioxide laser].
    17111Destruction ... 15 or more lesions [micro-ablative carbon dioxide laser].
    64566Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming.
    11980Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets beneath the skin).
    96372Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular.
    J0585Injection, onabotulinumtoxinA, 1 unit.
    J0586Injection, abobotulinumtoxinA, 5 units.
    J0587Injection, rimabotulinumtoxinB, 100 units.
    1–10 of 32
    1/4
    ICD-10 codes (covered and not covered as specified)ICD-10
    N90.5Atrophy of vulva.
    N94.10Dyspareunia.
    N94.11Dyspareunia (other specified).
    N94.19Dyspareunia (other specified).
    N95.2Postmenopausal atrophic vaginitis.
    F52.0Sexual dysfunction not due to a substance or known physiological condition, female.
    F52.1Sexual dysfunction not due to a substance or known physiological condition, female (additional codes range).
    F52.22Sexual dysfunction not due to a substance or known physiological condition, female (range).
    F52.31Sexual dysfunction not due to a substance or known physiological condition, female (range).
    F52.5Sexual dysfunction not due to a substance or known physiological condition, female (range).
    1–10 of 14
    1/2

    Prior authorization, documentation, and prescribing guidance

    Prior Authorization

    Codes identified for review/prior authorization

    Codes listed in the coding section may require review and/or prior authorization depending on the plan. Providers should verify billing codes and check plan-specific prior authorization requirements before submitting services.

    • Affected codes called out in policy coding section (e.g., 0552T, 0672T, 17110, 17111, 64566, 11980, 96372)
    • Numerous J‑codes for injectable agents and products listed in coding section
    Denial Risk

    FDA safety and marketing warning

    The FDA has issued public safety statements warning about marketing of laser and other energy‑based devices for “vaginal rejuvenation” without adequate evidence of safety and effectiveness. Providers should be aware that FDA identified reports of burns, scarring, pain, and chronic symptoms and cautioned against off‑label promotional claims.

    • FDA safety concern: vaginal burns, scarring, dyspareunia, recurring/chronic pain
    • Devices may be cleared for other indications but not for vaginal rejuvenation
    Denial Risk

    FDA warning on energy‑based devices

    The FDA specifically cautions that lasers and other energy‑based devices have not been evaluated or confirmed as safe and effective for vaginal rejuvenation or treatment of gynecologic conditions beyond cleared indications. Use of these devices for vaginal rejuvenation is associated with possible serious harm and should be approached with caution; prior authorization is recommended where plan review is required.

    • Avoid use of energy‑based vaginal therapies outside FDA‑cleared indications
    • Document indication and informed consent if such therapies are considered
    Documentation Required

    Ospemifene prescribing considerations

    When prescribing ospemifene (Osphena), document the indication (moderate-to-severe dyspareunia due to vulvovaginal atrophy related to menopause), confirm dosing (60 mg daily with food), and consider uterine status and need for progestin in women with a uterus due to endometrial cancer risk; avoid use in contraindicated conditions.

    • Indication: moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA) from menopause
    • Dose: 60 mg orally once daily with food
    • Contraindications/precautions: history of estrogen‑dependent neoplasia, abnormal genital bleeding, active or prior thromboembolic disease, severe hepatic impairment
    • Consider progestin in women with a uterus; use shortest duration consistent with treatment goals
    Documentation Required

    Trial outcome and safety documentation (ospemifene)

    Clinical trials of ospemifene evaluated vaginal maturation index (parabasal and superficial cell percentages), vaginal pH, severity scores for dryness/dyspareunia, FSFI domain and total scores, and safety endpoints including endometrial assessments and laboratory monitoring. Document trial outcomes and safety monitoring when applicable.

    • Co‑primary endpoints: maturation index components and vaginal pH; symptom severity (dryness/dyspareunia)
    • FSFI improvements observed in trials (domains and total score)
    • Safety monitoring included physical exam, Pap test, labs, endometrial thickness/histology
    Documentation Required

    Bremelanotide (Vyleesi) prescribing limits

    Bremelanotide (Vyleesi) prescribing limits must be followed: indicated only for pre‑menopausal women with acquired, generalized HSDD; limit dosing to no more than 1 dose in 24 hours and no more than 8 doses per month; discontinue if no benefit after 8 weeks.

    • Indication: pre‑menopausal women with acquired, generalized HSDD causing marked distress
    • Dosing limits: ≤1 dose per 24 hours; ≤8 doses per 30 days
    • Discontinue after 8 weeks without benefit
    Documentation Required

    Administrative documentation and policy history

    Document prior authorization decisions, review dates, policy history, and plan‑specific administrative requirements. Providers should refer to the Aetna Clinical Policy Bulletin and the member's benefit plan for plan‑level prior authorization, coverage determinations, and exclusions.

    • Effective date: 2001-11-09; Next review: 06/13/2024 (per policy header)
    • Check member plan for exclusions of sexual dysfunction drugs or supplies
    • Keep records of prior authorization submissions and rationale
    Note

    Consider conservative therapy first

    Conservative therapy should be attempted first in most cases of FSD when appropriate: education, lubricants, behavioral interventions (sensate focus), counseling, psychotherapy, and addressing contributing medical or medication causes are first‑line approaches prior to advanced or procedural therapies.

    • First‑line: education, lubricants, topical measures to minimize dyspareunia, sensate focus exercises
    • Address reversible contributors: medication review, psychiatric or relationship factors, medical conditions
    Note

    Therapy sequencing observation

    Therapy sequencing observations: across studies hormonal therapies showed the most consistent benefit for FSD symptoms; non‑hormonal and device‑based options often lack high‑quality evidence. Sequence therapies starting with conservative and hormonal options where appropriate, reserving experimental or device‑based interventions for selected cases with documented rationale.

    • Hormonal therapies most consistently effective across studies
    • Non‑hormonal options (e.g., HA, topical agents) have mixed/limited high‑quality evidence
    • Device‑based therapies (lasers, RF) are considered experimental/investigational by Aetna
    Step Therapy

    Step therapy — not specified

    Step therapy is not specified in this policy. The policy notes adjunctive options (e.g., hyaluronic acid suppositories, topical agents) and highlights limited evidence for many interventions; follow plan‑specific utilization management for any step therapy requirements.

    • No formal step‑therapy algorithm provided in this CPB
    • Providers must follow any plan‑level step therapy or prior authorization rules

    Clinical background and context

    Female sexual dysfunction (FSD) encompasses a range of disorders affecting desire, arousal, orgasm and pain, including vaginal dryness, arousal disorders, dyspareunia (painful intercourse), inability to achieve orgasm, and loss of clitoral sensation. Evaluation should consider the psychosocial context and identify treatable etiologies first, with conservative non‑pharmacologic and standard hormonal therapies generally favored before experimental or device‑based interventions.

    Key terms and definitions

    inv-31: Biothesiometry — technique description for sensitivity testing
    TechniqueUses a small cylindrical instrument to evaluate sensitivity of the clitoris and labia to pressure and temperature
    PurposeAssess genital somatic sensory function to help evaluate neurologic contributions to sexual dysfunction
    Clinical evidence / limitationInsufficient evidence to support its clinical use for diagnosis of female sexual dysfunction (per policy)
    Example studyErol et al (2003): biothesiometry compared sensory thresholds at genital and extra-genital sites in diabetic vs control women (n=30 vs 20); differences in thresholds noted but not clearly linked to FSD
    inv-32: Ospemifene (Osphena) — SERM approved indication and dosing note
    Drug / classOspemifene (Osphena), a selective estrogen receptor modulator (estrogen agonist/antagonist)
    Approved indicationTreatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause
    Recommended dose60 mg tablet once daily with food
    Key safety / prescribing notesBlack box warnings for endometrial cancer and cardiovascular disorders; contraindicated in active or history of estrogen‑dependent neoplasia and thromboembolic disease; use shortest duration consistent with goals
    Use in special populationsNot studied in severe hepatic impairment — use not recommended; Pregnancy Category X
    inv-33: Vulvovaginal atrophy (VVA) — definition and clinical features
    DefinitionGenitourinary symptoms due to estrogen deficiency in postmenopausal women characterized by vaginal dryness, dyspareunia and changes in vaginal epithelium and pH
    Common clinical featuresVaginal dryness, painful intercourse (dyspareunia), mucosal thinning, increased vaginal pH and altered maturation index
    EvaluationDiagnosis based on history, exam and, when indicated, measures such as vaginal maturation index and pH; consider psychosocial contributors before medical therapy
    inv-34: FSIAD / HSDD / FSAD — diagnostic category definitions and DSM-5 note
    FSIAD / HSDD / FSADDiagnostic categories for female sexual disorders; DSM-5 merged hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD) into female sexual interest/arousal disorder (FSIAD)
    Diagnostic requirementDiagnosis requires that symptoms (eg, low desire or arousal) cause personal distress and are not better explained by medical/psychiatric conditions, relationship problems, or substances
    Clinical evaluationAssessment includes medical and sexual history, physical exam as indicated, and selective laboratory testing when warranted
    inv-35: Hypoactive sexual desire disorder (HSDD) — definition and diagnostic context
    DefinitionAcquired, generalized low sexual desire causing marked distress or interpersonal difficulty, not due to a co-existing medical/psychiatric condition, relationship problems, or substance effects
    Treatment considerationsEvaluate for and address reversible causes; document diagnosis and treatment response per prescribing guidance
    inv-36: Hyaluronic acid (HA) vaginal suppositories — description and use in studies
    DescriptionTopical intravaginal suppositories containing hyaluronic acid, often combined with vitamins A and E or other agents, used to treat vaginal atrophy, dryness and dyspareunia
    Reported effectsStudies and a systematic review suggest HA-containing suppositories may improve dyspareunia, mucosal inflammation, vaginal dryness, bleeding, fibrosis and cellular atypia in women after pelvic radiotherapy
    Evidence limitationsIncluded studies were heterogeneous, generally small (total N=376 in reviewed cancer‑survivor population) and limit meta-analysis; larger randomized placebo‑controlled trials are needed
    Clinical rolePotential adjunct or alternative for women (including cancer survivors) who cannot use estrogens, but not established as standard therapy pending further trials

    Policy dates and document history